<DOC>
	<DOC>NCT02183220</DOC>
	<brief_summary>The objective of the study was to evaluate the efficacy, safety and tolerability of a single peroral dose of 0.5 g and 1.0 g metamizol relative to placebo and 1.0 g acetylsalicylic acid in 2 episodes of moderate tension headache.</brief_summary>
	<brief_title>Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Dipyrone</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Male and female patients between 18 and 65 years old Moderate episodic tension headache according to International Headache Society (I.H.S.) classification 2.1 (2.1.1 and 2.1.2) for at least one year At least two episodes of tension headache per month in the last three months prior to enrolment into this trial The episodes of tension headaches were usually treated by the patient successfully with a nonopioidanalgesic First episodic headache occurred at an age under 50 years Written informed consent according to Good Clinical Practice (GCP) and local regulations The patient was able to fill in the Patient's Diary The patient usually needs for successful treatment of tension headache "Over The Counter" (OTC) analgesic in doses exceeding the doses tested here The patient takes an OTCanalgesic normally at the first signs of an episode of tension headache The patient has more than 15 episodes of tension headache per month Female patients whose episodic tension headache is strongly correlated with the start of hormonal contraception Concomitant treatment with (non) prescriptional analgesics Pre (less than 4 weeks prior to inclusion in this trial) and/or concomitant treatment with an antidepressive and/or antipsychotic drug Pre (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug such as NSAIDs (NonSteroidal Anti Inflammatory Drugs), propanolol, metroprolol, flunarizin, cyclandelate, valproicacid, serotonergic antagonists, ergotamine, dihydroergotamines and benzodiazepines that may influence the headache symptomatology Use of benzodiazepines in the previous 24 hours to the administration of the study drug. Occasional use of benzodiazepines up to 3 per week is allowed Use of any drug with analgesic properties in the previous 24 hours to the administration of the study drug Concomitant treatment with any drug containing ASA and/or metamizol Concomitant treatment with anticoagulants such as heparin or coumarinderivatives Alcohol and drug abuse according to DSMIV (Diagnostic and Statistical Manual of Mental Disorders ) Female patients in childbearing age not using adequate means of birth control Pregnancy and/or lactation Gastrointestinal ulcers Liver and/or renal disease Bronchial asthma Relevant allergy or known hypersensitivity to the investigational drugs, its excipients and/or to other NSAIDs Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial Patients with active gastroesophageal flux disease (Amendment number 1) Concomitant treatment with analgesics or any other drug that may have influenced the headache symptomatology including metamizol or ASA , was referred to its use during the headache episodes under evaluation. As long as appropriate washout periods were respected, analgesics were allowed in between the episodes of tension headache (TH) and their use as a rescue medication did not lead to the exclusion of the patient (Amendment number 2)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>